Abstral Approval May Fetch ProStrakan The Valuation It's After
This article was originally published in The Pink Sheet Daily
Executive Summary
A second U.S. product approval in two weeks, plus a partner-driven re-financing, means the price of ProStrakan just went up.
You may also be interested in...
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Current European-based specialty pharma companies are in transition, awaiting key regulatory decisions, overhauling management or engaged in M&A. Their fates will help answer a critical question: under what circumstances can this class of companies continue to deliver long term growth as independent entities?
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Current European-based specialty pharma companies are in transition, awaiting key regulatory decisions, overhauling management or engaged in M&A. Their fates will help answer a critical question: under what circumstances can this class of companies continue to deliver long term growth as independent entities?
European Spec Pharma Testing New Niches: Emerging Markets, Novel Products
Many struggling European specialty pharma companies are grappling with whether to move outside the traditional business mold by venturing beyond Europe, including into emerging markets, and how to develop differentiated products with potential for transformative growth.